New hope for CMV in pregnancy: drug trial aims to shield newborns
NCT ID NCT05446571
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This study tests if a drug called letermovir works better than valaciclovir to stop cytomegalovirus (CMV) from passing to the baby during pregnancy. About 46 pregnant women with a CMV-infected fetus will be randomly assigned to one of the two drugs. The goal is to see which drug clears the virus from the baby's blood at birth and reduces long-term health problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Necker - Enfants malades
RECRUITINGParis, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.